Umberto Malapelle: Costs of biomarker testing in advanced non-small cell lung cancer
Umberto Malapelle, Associate Professor at the School of Medicine at the University of Naples Federico, shared an article on LinkedIn:
“Proud to be part of this international group of collegues!
“Widespread adoption of NGS may enable more efficient use of limited healthcare resources.”
Costs of biomarker testing in advanced non-small cell lung cancer: a global study comparing next-generation sequencing and single-gene testing.
Authors: Umberto Malapelle, et al.
Svetlana Nikic, Founder of Precision Oncology Consulting, reshared the post on X, adding:
“This study, conducted across 10 pathology centers in 10 countries, compared the real-world costs of NGS and single-gene testing (SGT) for advanced NSCLC across three time-based scenarios.
Analyzing data from 4,491 patients, the study found that mean per-patient costs for NGS decreased relative to SGT over time.
In the real-world model, NGS costs were 18% lower than SGT in the ‘Starting Point’ (SP) scenario and 26% lower in the ‘Current Practice’ (CP) scenario. In the standardized model, NGS became more cost-effective than SGT when 10 biomarkers were tested in the SP scenario and 12 biomarkers in the CP scenario.
The study concluded that NGS is more cost-effective than SGT for a NSCLC biomarker testing when testing 10 or more biomarkers.
This type of studies is a key for wider adoption and reimbursement of NGS across European healthcare.
Congratulations Umberto Malapelle, Albrecht Stenzinger and many others involved!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023